Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
Background: Imbalance between cell proliferation and apoptosis underlies the development of pulmonary arterial hypertension (PAH). Current vasodilator treatment of PAH does not target the uncontrolled proliferative process in pulmonary arteries. Proteins involved in the apoptosis pathway may play a...
Main Authors: | Isabel Blanco, Maribel Marquina, Olga Tura-Ceide, Elisabet Ferrer, Ana M. Ramírez, Manuel Lopez-Meseguer, Maria Callejo, Francisco Perez-Vizcaino, Victor Ivo Peinado, Joan Albert Barberà |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1145994/full |
Similar Items
-
Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways
by: Daniel Aguilar, et al.
Published: (2022-06-01) -
Updated Perspectives on Pulmonary Hypertension in COPD
by: Blanco I, et al.
Published: (2020-06-01) -
Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease.
by: Tanja Paul, et al.
Published: (2018-01-01) -
Editorial: Metabolic changes in vascular disorders: A path for early diagnosis and new therapeutic targets
by: Sana Ayyoub, et al.
Published: (2023-03-01) -
Progenitor cell mobilisation and recruitment in pulmonary arteries in chronic obstructive pulmonary disease
by: Olga Tura-Ceide, et al.
Published: (2019-04-01)